Benzodiazepines are often prescribed longer than recommended, risking chronic use. Pharmacists play a key role in identifying risks and supporting deprescription.
Benzodiazepine prescriptions often exceed recommended limits
Benzodiazepines, commonly used for anxiety and insomnia, are frequently prescribed for longer than guidelines recommend. Studies show that nearly one-third of patients on anxiolytic benzodiazepines and nearly two-thirds on hypnotic benzodiazepines receive prescriptions beyond the maximum recommended duration.Risks of prolonged use
While these medications are effective for quickly relieving symptoms, long-term use increases risks such as dependence, withdrawal symptoms, cognitive decline, falls in older adults, and traffic accidents. These dangers are well-documented in medical literature.Limited use and specific indications
Benzodiazepine anxiolytics are meant for temporary relief of anxiety symptoms, not for treating the underlying causes of anxiety disorders. They are typically used for conditions like generalized anxiety, panic disorder, or social anxiety, and should be used alongside non-drug treatments. Their use should not exceed 12 weeks, including a gradual tapering period.Hypnotic benzodiazepines have stricter limits
Hypnotic benzodiazepines are even more restricted, intended only for short-term use in cases of occasional insomnia. For longer-term sleep issues, cognitive behavioral therapy is preferred as the first-line treatment. When necessary, hypnotic benzodiazepines should not be used for more than four weeks, with a plan for gradual discontinuation.Pharmacists play a key role in deprescription
Pharmacists are crucial in identifying high-risk situations during prescription renewals and supporting the deprescription of benzodiazepines. They can use tools like the cognitive attachment scale to benzodiazepines (ECAB) to detect signs of misuse or addiction.Resources for better prescription practices
To assist healthcare professionals, the Health Insurance Fund launched resources in November 2025, available on the Ameli.fr website. These include videos, screening tools, informational brochures, and guidance on deprescribing to ensure benzodiazepines are used safely and appropriately.